Where research is preliminary, this is flagged in the text. Absence of long-term human data should be assumed for most peptides covered here.
Moving a peptide from animal models into a first-in-human study requires careful dose translation. AOD-9604 (a 16-amino acid fragment of human growth hormone) has been tested in rodents for cartilage repair and metabolic effects. The allometric scaling and safety factor methods used for this peptide follow standard practice, but the details matter. This article walks through the steps, using AOD-9604 as the primary example and referencing KPV, GHK-Cu, Selank, Argireline, and IGF-1 LR3 where relevant.
What the Translation Process Requires
Dose translation starts with a no-observed-adverse-effect level (NOAEL) from animal studies. For AOD-9604, published rodent work often uses doses in the range of 50 to 200 mcg per kg per day. That range comes from cartilage repair models and metabolic studies in rats and mice. The first step is to convert that animal dose to a human equivalent dose (HED) using body surface area normalization.
Allometric scaling assumes that physiological rates scale with body weight raised to a power, usually 0.67 or 0.75. For a rat weighing 0.25 kg and a human weighing 70 kg, the scaling factor is roughly 6.2 when using the 0.67 exponent. So a rat dose of 100 mcg/kg becomes a human equivalent of about 16 mcg/kg. That is the starting point, not the final dose.
Safety factors are then applied. A typical first-in-human study uses a safety factor of 10 when the animal data are solid and the mechanism is well understood. For peptides like AOD-9604, where the human data are limited, a factor of 10 to 30 is common. This means the starting human dose would be in the neighborhood of 0.5 to 1.6 mcg/kg. That is a conservative range, but it reflects the uncertainty in cross-species translation.
Worked Example from a Published Protocol
Consider a rodent study that used AOD-9604 at 150 mcg/kg/day for cartilage repair. The NOAEL in that study was 150 mcg/kg, with no adverse effects observed at that level. To translate:
- Convert rat dose to HED: 150 mcg/kg divided by 6.2 = 24.2 mcg/kg.
- Apply a safety factor of 10: 24.2 divided by 10 = 2.4 mcg/kg.
- For a 70 kg human, the starting dose would be 168 mcg total.
This is a worked example only. It does not suggest a dose for human use. The numbers illustrate the method. A similar approach applies to KPV (a tripeptide with anti-inflammatory activity). For KPV, rodent studies often use 1 to 5 mg/kg, and the HED calculation would follow the same steps. The safety factor might be higher for KPV because the mechanism is less well characterized than AOD-9604's.
For comparison, GHK-Cu (a copper-binding tripeptide) has been studied in wound healing at doses of 1 to 10 mg/kg in rodents. The allometric scaling for GHK-Cu would yield a human equivalent of roughly 0.16 to 1.6 mg/kg before safety factors. Selank (a synthetic peptide with anxiolytic properties) is often given intranasally at 100 to 300 mcg per rat, which translates to a much lower human dose on a per-kg basis. Argireline (acetyl hexapeptide-8) is used topically, so systemic translation is less relevant. IGF-1 LR3 (a long-acting IGF-1 analog) has a narrower therapeutic window and typically requires a higher safety factor due to its growth-promoting effects.
Stability and Formulation Considerations
Dose translation is not just about the number. The stability of the peptide in formulation affects the actual dose delivered. AOD-9604 is relatively stable in aqueous solution at pH 6 to 7, but it can degrade if stored at room temperature for more than a few days. Lyophilized powder is more stable, with a shelf life of 12 to 24 months at -20°C. Reconstitution in sterile saline or phosphate-buffered saline is typical for research use.
For first-in-human studies, the formulation must be sterile and free of endotoxins. The dose must be adjusted for the peptide content of the vial, which is usually 90 to 95% by HPLC. If a vial contains 5 mg of AOD-9604 and the purity is 92%, the actual peptide is 4.6 mg. That correction matters when calculating the dose for a 70 kg human at 2.4 mcg/kg, which would require 168 mcg of pure peptide. You would need to draw 183 mcg of the 92% material to get 168 mcg of pure AOD-9604.
Stability studies for AOD-9604 show that it is stable for 24 hours at room temperature after reconstitution, and for 7 days at 4°C. For longer storage, aliquots should be frozen at -20°C or -80°C. Repeated freeze-thaw cycles reduce activity, so single-use aliquots are preferred. These details are often overlooked in preclinical work but become critical in a clinical trial setting.
Common Pitfalls in the Literature
Several errors appear repeatedly in published dose translation studies. The first is using body weight scaling instead of body surface area. This leads to a human dose that is too high by a factor of 6 to 12. For AOD-9604, a rat dose of 150 mcg/kg scaled by body weight would give a human dose of 150 mcg/kg, or 10.5 mg for a 70 kg human. That is far above the HED of 24 mcg/kg. The error is easy to spot but still common.
A second pitfall is ignoring the difference in metabolic rate between species. Mice and rats clear peptides faster than humans, so the same plasma concentration requires a higher dose per kg in rodents. Allometric scaling accounts for this, but only if the correct exponent is used. For peptides, the exponent is often 0.75 rather than 0.67, which changes the HED by about 20%. For AOD-9604, using 0.75 instead of 0.67 would give a rat-to-human factor of 7.4 instead of 6.2, lowering the HED from 24.2 to 20.3 mcg/kg.
A third pitfall is failing to apply a safety factor at all. Some studies jump from animal efficacy doses directly to human doses, which is not acceptable for first-in-human work. The safety factor exists to account for unknown differences in receptor binding, off-target effects, and immune responses. For AOD-9604, the safety factor is usually 10, but for peptides with less human data, like KPV or Selank, a factor of 30 or more may be used.
Statistical power analysis for KPV studies can inform the choice of animal doses, which then feeds into the translation. A study with low power may miss a toxic effect at a high dose, leading to an overestimated NOAEL. Statistical power analysis for KPV anti-inflammatory rodent studies covers this issue in detail. Similarly, sample size estimation for KPV anti-inflammatory rodent trials explains how to avoid underpowered toxicity screens.
Blinding and randomization also matter for dose translation. If the animal study was not blinded, the NOAEL may be biased. Blinding and randomization protocols for KPV anti-inflammatory trials describes how to design a study that produces reliable NOAEL data. For AOD-9604 specifically, blinded outcome assessment in AOD-9604 rodent cartilage repair studies is directly relevant to the quality of the preclinical data used in translation.
Compliance Closing
We do not endorse or recommend the use of any peptide for any purpose other than legitimate research. The methods described here are for researchers planning preclinical or clinical studies. Allometric scaling and safety factor methodology are standard tools, but they require careful application. The numbers in this article are illustrative, not prescriptive. Always consult regulatory guidelines and a qualified toxicologist before designing a first-in-human study.
Where research is preliminary, this is flagged in the text. Absence of long-term human data should be assumed for most peptides covered here.